Form 8-K NEKTAR THERAPEUTICS For: Jul 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Nektar Therapeutics (NKTR) Lost Less than Expected in Q2
July 31, 2014 5:29 PM EDTNektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.26), $0.11 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $28.5 million versus the consensus estimate of $19.76 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
... More